To include your compound in the COVID-19 Resource Center, submit it here.

FDA places clinical hold on Ph I of Epizyme's tazemetostat

Epizyme Inc. (NASDAQ:EPZM) said FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma during a

Read the full 288 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE